Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression

BACKGROUND: It is currently unknown whether early B cell reconstitution (EBR) in MS patients under rituximab is associated with a risk of relapse or progression. OBJECTIVES: Analyzing EBR in rituximab-treated patients and its putative association with clinical findings. METHODS: Prospective lymphocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorcet, Guillaume, Migné, Hugo, Biotti, Damien, Bost, Chloé, Lerebours, Fleur, Ciron, Jonathan, Treiner, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159933/
https://www.ncbi.nlm.nih.gov/pubmed/35652942
http://dx.doi.org/10.1007/s00415-022-11197-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159933/
https://www.ncbi.nlm.nih.gov/pubmed/35652942
http://dx.doi.org/10.1007/s00415-022-11197-6

Ejemplares similares